Vepdegestrant improved progression-free survival in patients with estrogen receptor 1 mutations in advanced ER-positive, HER2-negative breast cancer. Among patients with estrogen receptor-positive, ...

The Canon RF 200-800mm f/6.3-9 IS USM is the reigning superzoom champion in terms of focal range and is impressively lightweight and compact for its reach. However, its mediocre maximum aperture does ...

Josh Herrin made history on Saturday at Daytona International Speedway when he became the first rider in Daytona 200 history to win “The Great American Motorcycle Race” three times in a row. It was ...

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in patients with BRCA1/2 mutations. Among patients with early-stage ...

In this post-pandemic world, it’s surprisingly (and frustratingly) rare to find a new car for under $30,000. Various factors are responsible, including emissions rules and the inexorable popularity of ...

Ashley Fricker has more than a decade of experience as a finance contributor and editor, and has specialized in the credit card industry since 2015. Her credit card commentary is featured on national ...

The arrival of the MG Cyberster marks a significant moment in the story of the Chinese-owned brand. With the old Morris Garages MG having a rich history of sports cars, any flagship performance ...

The successor to the MG ZS EV will be unveiled in a matter of weeks, the brand has confirmed, and the all-new, all-electric small SUV will be called the MGS5 EV. Of course, we already had a very ...

MG has sharpened prices for its ZS EV as the electric SUV enters runout mode, with new drive-away pricing that sees savings of up to $14,791. Stock of the entry-level Excite is already gone, and MG ...

Your browser does not support the audio element. The MG Comet Blackstorm edition has been launched at a price of Rs 7.80 lakh (ex-showroom), plus Rs 2.50 per km for ...

Sales of breast cancer treatment Verzenio also are booming at $5.3 billion, which was a 37% increase from 2023.

All patients received an aromatase inhibitor and a CDK4/6 inhibitor—either Lilly’s Verzenio, Novartis’ Kisqali or Pfizer’s Ibrance—as their first-line treatment. Physicians monitored ...